Gustavo C Leal
Overview
Explore the profile of Gustavo C Leal including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
235
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Leal G, Lima-Araujo I, Roiter D, Caliman-Fontes A, Mello R, Kapczinski F, et al.
Eur Arch Psychiatry Clin Neurosci
. 2024 Dec;
PMID: 39680139
Arketamine (R-ketamine), an enantiomer of ketamine, has historically been less studied than esketamine (S-ketamine) and the racemic mixture. Recent preclinical studies suggest that arketamine may offer prolonged antidepressant effects and...
2.
Caliman-Fontes A, Vieira F, Leal G, Carneiro B, Quarantini-Alvim Y, Andrade T, et al.
Schizophr Res
. 2024 Aug;
271:355-370.
PMID: 39098303
Introduction: Catatonia, documented since the 19th century, remains a significant challenge in terms of recognition and treatment. Over the last two decades, ketamine has brought new perspectives to psychiatry, sparking...
3.
Carneiro B, Franco Guerreiro-Costa L, Lins-Silva D, Faria Guimaraes D, Souza L, Leal G, et al.
Cureus
. 2024 Apr;
16(3):e56910.
PMID: 38665721
Despite the hardships of major depressive disorder (MDD), biomarkers for the diagnosis and pharmacological management of this condition are lacking. MicroRNAs are epigenetic mechanisms that could provide promising MDD biomarkers....
4.
Alves-Pereira R, Fontes M, Cordeiro V, Bandeira I, Faria-Guimaraes D, Silva S, et al.
Clin Neuropharmacol
. 2024 Jan;
47(1):17-21.
PMID: 38194244
Objective: Converging evidence supports the role of the glutamate, an excitatory amino acid neurotransmitter, in the pathophysiology of obsessive-compulsive disorder (OCD). Ketamine and esketamine, both noncompetitive N -methyl- d -aspartate...
5.
Caliman-Fontes A, Leal G, Gadelha A, Quarantini L
Braz J Psychiatry
. 2023 Oct;
45(5):461-462.
PMID: 37792800
No abstract available.
6.
Echegaray M, Mello R, Magnavita G, Leal G, Correia-Melo F, Jesus-Nunes A, et al.
Trends Psychiatry Psychother
. 2023 Sep;
PMID: 37717263
Background: Ketamine and esketamine have both shown significant antidepressant effects in treatment-resistant depression (TRD), and conflicting evidence suggests that induced dissociation by these drugs can be a clinical predictor of...
7.
Bandeira I, Leal G, Correia-Melo F, Souza-Marques B, Silva S, Lins-Silva D, et al.
J Psychiatr Res
. 2023 Jun;
164:229-234.
PMID: 37385001
There are significantly fewer options for the treatment of bipolar depression than major depressive disorder, with an urgent need for alternative therapies. In this pilot study, we treated six subjects...
8.
Leal G, Souza-Marques B, Mello R, Bandeira I, Caliman-Fontes A, Carneiro B, et al.
J Affect Disord
. 2023 Mar;
330:7-15.
PMID: 36871913
Background: Racemic ketamine is a mixture of (R)-ketamine (arketamine) and (S)-ketamine (esketamine), with the latter regarded as the main isomer for antidepressant effects. However, preclinical data and one open-label human...
9.
Beanes G, Caliman-Fontes A, Souza-Marques B, Silva H, Leal G, Carneiro B, et al.
Clin Neuropharmacol
. 2022 Sep;
45(6):151-156.
PMID: 36093918
Objective: This study aimed to evaluate the effect of genetic variants in glutamate ionotropic receptor N-methyl- d -aspartate type subunit 2B ( GRIN2B ), glutamate ionotropic receptor α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid type...
10.
Souza-Marques B, Telles M, Leal G, Faria-Guimaraes D, Correia-Melo F, Jesus-Nunes A, et al.
J Clin Psychopharmacol
. 2022 Jun;
42(4):408-412.
PMID: 35727083
Purposes/background: The aims of the study were to assess subanesthetic esketamine as an antidepressant for major depressive disorder with psychotic features (PMDD) and to compare posttreatment symptoms among those with...